Champions Oncology, Inc.
$6.08
▼
-2.45%
2026-04-21 06:15:00
www.championsoncology.com
NCM: CSBR
Explore Champions Oncology, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$84.36 M
Current Price
$6.08
52W High / Low
$9.63 / $5.5
Stock P/E
—
Book Value
$0.31
Dividend Yield
—
ROCE
57.07%
ROE
-47.59%
Face Value
—
EPS
$-0.18
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
213
Beta
0.4
Debt / Equity
114.19
Current Ratio
0.98
Quick Ratio
0.94
Forward P/E
57.5
Price / Sales
1.38
Enterprise Value
$77.82 M
EV / EBITDA
-100.8
EV / Revenue
1.34
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
Cons
- Leverage is relatively high.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Alpha Cognition Inc. Common Stock | $6.89 | — | $150.02 M | — | -23.03% | -40.68% | $11.54 / $3.97 | $2.88 |
| 2. | Praxis Precision Medicines, Inc. | $340.84 | — | $9.47 B | — | -37.15% | -45.83% | $356 / $28.79 | $34.85 |
| 3. | Century Therapeutics, Inc. | $2.34 | — | $467.28 M | — | -5.16% | -5.98% | $3.04 / $0.43 | $1.82 |
| 4. | Black Diamond Therapeutics, Inc. | $3.05 | 7.84 | $175.3 M | — | 15.61% | 22.88% | $4.94 / $1.31 | $1.96 |
| 5. | OmniAb, Inc. | $1.55 | — | $237.44 M | — | -24.23% | -23.36% | $2.29 / $1.22 | $1.85 |
| 6. | Processa Pharmaceuticals, Inc. | $2.71 | — | $8.25 M | — | -250.81% | -3.73% | $19.63 / $1.76 | $2.17 |
| 7. | Amicus Therapeutics, Inc. | $14.46 | — | $4.54 B | — | 4.84% | -11.58% | $14.48 / $5.51 | $0.88 |
Quarterly Results
Figures shown in M / B
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|---|
| Sales | 16.56 M | 15.04 M | 13.99 M | 12.36 M | 17.04 M | — |
| Operating Profit | -0.19 M | 0.18 M | -0.51 M | -1.71 M | 4.5 M | — |
| Net Profit | -0.28 M | 0.3 M | -0.47 M | -1.83 M | 4.5 M | — |
| EPS in Rs | -0.02 | 0.02 | -0.03 | -0.13 | 0.32 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 56.94 M | 50.16 M | 53.87 M | 49.11 M |
| Operating Profit | 4.85 M | -6.92 M | -4.45 M | 0.61 M |
| Net Profit | 4.7 M | -7.28 M | -5.33 M | 0.55 M |
| EPS in Rs | 0.34 | -0.52 | -0.38 | 0.04 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 32.34 M | 26.13 M | 34.31 M | 35.38 M |
| Total Liabilities | 28.57 M | 28.04 M | 29.68 M | 26.28 M |
| Equity | 3.77 M | -1.9 M | 4.64 M | 9.1 M |
| Current Assets | 22.37 M | 13.64 M | 19.46 M | 19.66 M |
| Current Liabilities | 23.85 M | 21.54 M | 21.73 M | 17.48 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 7.39 M | -6.14 M | 3.97 M | 6.5 M |
| Investing CF | -0.39 M | -0.84 M | -2.87 M | -2.38 M |
| Financing CF | 0.17 M | -0.53 M | 0.01 M | 0.21 M |
| Free CF | 7 M | -6.97 M | 1.1 M | 4.11 M |
| Capex | -0.39 M | -0.84 M | -2.87 M | -2.38 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -6.9% | 9.69% | — | — |
| Earnings Growth % | -36.38% | -1073.54% | — | — |
| Profit Margin % | -14.51% | -9.9% | 1.12% | — |
| Operating Margin % | -13.8% | -8.26% | 1.24% | — |
| Gross Margin % | 41.38% | 45.18% | 51.88% | — |
| EBITDA Margin % | -10.08% | -4.09% | 4.55% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.